This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Newsramp
newsramp.com
did:plc:xlsujlrwr5xpfxgaf4pixhri
Helix BioPharma reduces losses, refocuses on NSCLC therapy L-DOS47, receives positive FDA feedback, and strategically repositions for future oncology innovation. New leadership drives targeted approach to cancer treatment. #Oncology #BioPharma
2025-10-29T23:40:04.822Z